The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Garofalo Elizabeth A. since 2021.
This trader's CIK number is 1826361.
At the time of last reporting, Garofalo Elizabeth A. was the Officer of Acadia Pharmaceuticals Inc. (stock ticker symbol ACAD).
Also see all insider trading activities at Acadia Pharmaceuticals Inc.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2024 | XENE | 0 | $0 | 2,092 | $95,583 | 3,500 | $64,959 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | ACAD | 0 | $0 | 6,519 | $131,233 | 9,387 | $0 |
| 2024 | ACAD | 0 | $0 | 0 | $0 | 6,652 | $0 |
| 2022 | ACAD | 0 | $0 | 0 | $0 | 16,862 | $0 |
| 2021 | ACAD | 0 | $0 | 0 | $0 | 1,918 | $0 |
1. Xenon Pharmaceuticals Inc. (XENE)
2. Acadia Pharmaceuticals Inc (ACAD)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-03-08 | XENE | Sale | 2,092 | 45.69 | 95,583 |
| 2024-03-08 | XENE | Option Ex | 3,500 | 18.56 | 64,959 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-09-02 | ACAD | Sale | 1,600 | 25.98 | 41,560 |
| 2025-05-29 | ACAD | Option Ex | 9,387 | .00 | 0 |
| 2025-03-05 | ACAD | Sale | 4,919 | 18.23 | 89,673 |
| 2024-05-29 | ACAD | Option Ex | 6,652 | .00 | 0 |
| 2022-06-07 | ACAD | Option Ex | 6,391 | .00 | 0 |
| 2023-06-01 | ACAD | Option Ex | 8,552 | .00 | 0 |
| 2022-09-29 | ACAD | Option Ex | 1,919 | .00 | 0 |
| 2021-09-29 | ACAD | Option Ex | 1,918 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Garofalo Elizabeth A. (Officer of Acadia Pharmaceuticals Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.